Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in an In Vitro Pharmacokinetic Model of Infection
- 1 June 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (6) , 2451-2456
Abstract
An in vitro single-compartment dilutional pharmacokinetic model was used to study the pharmacodynamics of ceftaroline against Staphylococcus aureus (both methicillin-susceptible S. aureus [MSSA] and methicillin-resistant S. aureus [MRSA]). Mean serum free concentrations of ceftaroline (the active metabolite of the prodrug ceftaroline fosamil) dosed in humans at 600 mg every 12 h (q12h) were simulated, and activities against 12 S. aureus strains (3 MSSA strains and 9 MRSA strains, 3 of which had a vancomycin-intermediate phenotype) were determined. Ceftaroline produced 2.5- to 4.0-log 10 -unit reductions in viable counts by 24 h with all strains and a 0.5- to 4.0-log-unit drop in counts at 96 h. The antibacterial effect could not be related to the strain MIC across the ceftaroline MIC range from 0.12 to 2.0 μg/ml. In dose-ranging studies, the cumulative percentage of a 24-h period that the free drug concentration exceeded the MIC under steady-state pharmacokinetic conditions ( fT MIC ) of 24.5% ± 8.9% was associated with a 24-h bacteriostatic effect, one of 27.8% ± 9.5% was associated with a −1-log-unit drop, and one of 32.1% ± 8.1% was associated with a −2-log-unit drop. The MSSA and MRSA strains had similar fT MIC values. fT MIC values increased with increasing duration of exposure up to 96 h. Changes in ceftaroline population analysis profiles were related to fT MIC . fT MIC s of fT MIC of 25 to 30% would make a suitable pharmacodynamic index target, but fT MIC values of ≥50% are needed to suppress the emergence of resistance and require clinical evaluation.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus IsolatesAntimicrobial Agents and Chemotherapy, 2011
- Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2010
- In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber ModelAntimicrobial Agents and Chemotherapy, 2009
- Postantibiotic Effect of Ceftaroline against Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 2009
- Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2009
- In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic TargetAntimicrobial Agents and Chemotherapy, 2006
- Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion testsJournal of Antimicrobial Chemotherapy, 2005
- Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic ModelAntimicrobial Agents and Chemotherapy, 2003